Blauvelt A, Langley RG, Lacour JP, Toth D, et al. Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial. J Am Acad Dermatol 2022 Jul 18. pii: S0190-9622(22)02345.
PMID: 35863467